Generate Biomedicines (NASDAQ:GENB) Hits New 1-Year High – Should You Buy?

Shares of Generate Biomedicines Inc (NASDAQ:GENB) hit a new 52-week high during trading on Tuesday . The stock traded as high as $15.32 and last traded at $15.1680, with a volume of 97984 shares. The stock had previously closed at $14.46.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on GENB. Piper Sandler began coverage on Generate Biomedicines in a report on Tuesday, March 24th. They set an “overweight” rating and a $24.00 target price on the stock. Cantor Fitzgerald began coverage on Generate Biomedicines in a report on Tuesday, March 24th. They issued an “overweight” rating on the stock. Wall Street Zen upgraded Generate Biomedicines to a “hold” rating in a report on Saturday, March 14th. The Goldman Sachs Group began coverage on Generate Biomedicines in a report on Tuesday, March 24th. They issued a “buy” rating and a $26.00 price target on the stock. Finally, HC Wainwright began coverage on Generate Biomedicines in a report on Monday, April 13th. They issued a “buy” rating and a $16.00 price target on the stock. Six research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $23.20.

Generate Biomedicines Stock Up 6.6%

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.